Clinical Trial Update: Efficacy and Safety of AJU-S56 5% in Dry Eye Syndrome Patients [Phase 3]

View source ↗

Summary

Phase 3 trial updating efficacy and safety of AJU-S56 5% for dry eye syndromes.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Dry Eye Syndromes

Drugs mentioned

• AJU-S56 5%

Snippet

Sponsor: AJU Pharm Co., Ltd. | Conditions: Dry Eye Syndromes | Phase 3 | Status: RECRUITING